I am passionate about alpha 1-antitrypsin (AAT) deficiency. This rare condition exists in individuals who do not produce enough AAT to protect the lungs from emphysema. I head the area Alpha 1 Research Registry, which supports patients with this condition.
My patient care focus is to help patients understand their disease. Knowledge promotes better adherence to treatments and helps in symptom management.
The Ohio State University Wexner Medical Center brings together the best physicians in primary and specialty care. With so many expert colleagues on our team, I always know where to turn for difficult questions.
In my free time I enjoy reading, photography and sports with my grandkids. I also enjoy studying the night sky ... even in cloudy Ohio!
- Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2015
- Headed first commercial alpha 1-antitrypsin (AAT) infusion study, now standard of care
- Research lab funded for over 25 years to study mechanisms to protect the lung
- Training and working with MD and PhD students in my laboratory for three decades
Univ. of Arkansas
Univ. of Arkansas
7/1/1977 - 6/30/1979
Specialties and conditions I treat
- Pulmonary Disease
- Critical Care Medicine
- Pulmonary Medicine
- Pulmonary Disease, Chronic Obstructive
- Respiratory Insufficiency
- Respiration Disorders
- Pulmonary Emphysema
Locations where I practice
More about my work
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Critical Care Medicine)
American Board of Internal Medicine (Subspecialty: Pulmonary Disease)
Pulmonary, Allergy, Critical Care and Sleep Medicine
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/25/2016, Dr. Wewers has reported no financial relationships with medical device, research and/or drug companies.